Search

Your search keyword '"Scoccianti S"' showing total 346 results
Start Over Author "Scoccianti S"
346 results on '"Scoccianti S"'

2. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma

Author

Caccese, M., Desideri, I., Villani, V., Simonelli, M., Buglione, M., Chiesa, S., Franceschi, E., Gaviani, P., Stasi, I., Caserta, C., Brugnara, S., Lolli, I., Bennicelli, E., Bini, P., Cuccu, A.S., Scoccianti, S., Padovan, M., Gori, S., Bonetti, A., Giordano, P., Pellerino, A., Gregucci, F., Riva, N., Cinieri, S., Internò, V., Santoni, M., Pernice, G., Dealis, C., Stievano, L., Paiar, F., Magni, G., De Salvo, G.L., Zagonel, V., and Lombardi, G.

Published
2024
Full Text
View/download PDF

10. OC-0910 Immunogenicity after two/three doses of mRNA vaccine in cancer patients treated with radiotherapy

Author

Scoccianti, S., primary, Delli Paoli, C., additional, Infantino, M., additional, Paoletti, L., additional, Caini, S., additional, Meacci, F., additional, Russo, S., additional, Esposito, M., additional, Fondelli, S., additional, Grilli Leonulli, B., additional, Grossi, V., additional, Barca, R., additional, Alpi, P., additional, Furlan, F., additional, Perna, M., additional, Pino, M.S., additional, Martella, F., additional, Manfredi, M., additional, Stefanacci, M., additional, Bassetti, A., additional, Casprini, P., additional, and Fioretto, L., additional

Published
2023
Full Text
View/download PDF

11. PO-1736 The role of in vivo dosimetry in the continuous quality improvement of lung stereotactic treatments

Author

Esposito, M., primary, Mancosu, P., additional, Bruschi, A., additional, Ghirelli, A., additional, Pini, S., additional, Alpi, P., additional, Barca, R., additional, Delli Paoli, C., additional, Meacci, F., additional, Grilli Leonulli, B., additional, Fondelli, S., additional, Paoletti, L., additional, Scoccianti, S., additional, and Russo, S., additional

Published
2023
Full Text
View/download PDF

16. In-vivo and pre-treatment quality assurance software validation and verification

Author

Vanzi, E., Reversi, L., Giani, G., Arilli, C., Bonomo, P., Casati, M., Compagnucci, A., Greto, D., Marrazzo, L., Scoccianti, S., Pallotta, S., Bucciolini, M., Talamonti, C., MAGJAREVIC, Ratko, Editor-in-chief, Ladyzynsk, Piotr, Series editor, Ibrahim, Fatimah, Series editor, Lacković, Igor, Series editor, Rock, Emilio Sacristan, Series editor, and Jaffray, David A., editor

Published
2015
Full Text
View/download PDF

18. Brain metastases from primary colorectal cancer: Is radiosurgery an effective treatment approach? Results of a multicenter study of the radiation and clinical oncology Italian association (AIRO)

Author

Navarria, P, Minniti, G, Clerici, E, Comito, T, Cozzi, S, Pinzi, V, Fariselli, L, Ciammella, P, Scoccianti, S, Borzillo, V, Anselmo, P, Maranzano, E, Dell'Acqua, V, Jereczek-Fossa, B, Levra, N, Podlesko, A, Giudice, E, Di Monale E Bastia, M, Pedretti, S, Bruni, A, Zanetti, I, Borghesi, S, Busato, F, Pasqualetti, F, Paiar, F, Scorsetti, M, Navarria P., Minniti G., Clerici E., Comito T., Cozzi S., Pinzi V., Fariselli L., Ciammella P., Scoccianti S., Borzillo V., Anselmo P., Maranzano E., Dell'Acqua V., Jereczek-Fossa B., Levra N. G., Podlesko A. M., Giudice E., Di Monale E Bastia M. B., Pedretti S., Bruni A., Zanetti I. B., Borghesi S., Busato F., Pasqualetti F., Paiar F., Scorsetti M., Navarria, P, Minniti, G, Clerici, E, Comito, T, Cozzi, S, Pinzi, V, Fariselli, L, Ciammella, P, Scoccianti, S, Borzillo, V, Anselmo, P, Maranzano, E, Dell'Acqua, V, Jereczek-Fossa, B, Levra, N, Podlesko, A, Giudice, E, Di Monale E Bastia, M, Pedretti, S, Bruni, A, Zanetti, I, Borghesi, S, Busato, F, Pasqualetti, F, Paiar, F, Scorsetti, M, Navarria P., Minniti G., Clerici E., Comito T., Cozzi S., Pinzi V., Fariselli L., Ciammella P., Scoccianti S., Borzillo V., Anselmo P., Maranzano E., Dell'Acqua V., Jereczek-Fossa B., Levra N. G., Podlesko A. M., Giudice E., Di Monale E Bastia M. B., Pedretti S., Bruni A., Zanetti I. B., Borghesi S., Busato F., Pasqualetti F., Paiar F., and Scorsetti M.

Abstract

Objectives: The prognosis of brain metastatic colorectal cancer patients (BMCRC) is poor. Several local treatments have been used, but the optimal treatment choice remains an unresolved issue. We evaluated the clinical outcomes of a large series of BMCRC patients treated in several Italian centers using stereotactic radiosurgery (SRS). Methods: 185 BMCRC patients for a total of 262 lesions treated were evaluated. Treatments included surgery followed by post-operative SRS to the resection cavity, and SRS, either single-fraction, then hypofractionated SRS (HSRS). Outcomes was measured in terms of local control (LC), toxicities, brain distant failure (BDF), and overall survival (OS). Prognostic factors influencing survival were assed too. Results: The median follow-up time was 33 months (range 3-183 months). Surgery plus SRS have been performed in 28 (10.7%) cases, SRS in 141 (53.8%), and HSRS in 93 (35.5%). 77 (41.6%) patients received systemic therapy. The main total dose and fractionation used were 24Gy in single fraction or 24Gy in three daily fractions. Local recurrence occurred in 32 (17.3%) patients. Median, 6 months,1-year-LC were 86 months (95%CI 36-86), 87.2% ± 2.8, 77.8% ± 4.1. Median,6 months,1-year-BDF were 23 months (95%CI 9-44), 66.4% ± 3.9, 55.3% ± 4.5. Median,6 months,1-year-OS were 7 months (95%CI 6-9), 52.7% ± 3.6, 33% ± 3.5. No severe neurological toxicity occurred. Stage at diagnosis, Karnofsky Performance Status (KPS), presence and number of extracranial metastases, and disease-specific-graded-prognostic-assessment (DS-GPA) score were observed as conditioning survival. Conclusion: SRS/HSRS have proven to be an effective local treatment for BMCRC. A careful evaluation of prognostic factors as well as a multidisciplinary evaluation is a valid aid to manage the optimal therapeutic strategy for CTC patients with BMs.

Published
2020

19. PO-1067 Safety and Immunogenicity of Moderna COVID vaccine in radiotherapy patients

Author

Scoccianti, S., primary, Delli Paoli, C., additional, Paoletti, L., additional, Grilli Leonulli, B., additional, Russo, S., additional, Alpi, P., additional, Barca, R., additional, Fondelli, S., additional, Caini, S., additional, Infantino, M., additional, Manfredi, M., additional, Esposito, M., additional, Grossi, V., additional, Furlan, F., additional, Pino, M.S., additional, Martella, F., additional, Bassetti, A., additional, Casprini, P., additional, and Fioretto, L., additional

Published
2022
Full Text
View/download PDF

21. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO)

Author

Navarria, P, Minniti, G, Clerici, E, Tomatis, S, Pinzi, V, Ciammella, P, Galaverni, M, Amelio, D, Scartoni, D, Scoccianti, S, Krengli, M, Masini, L, Draghini, L, Maranzano, E, Borzillo, V, Muto, P, Ferrarese, F, Fariselli, L, Livi, L, Pasqualetti, F, Fiorentino, A, Alongi, F, di Monale, M, Magrini, S, Scorsetti, M, Navarria P., Minniti G., Clerici E., Tomatis S., Pinzi V., Ciammella P., Galaverni M., Amelio D., Scartoni D., Scoccianti S., Krengli M., Masini L., Draghini L., Maranzano E., Borzillo V., Muto P., Ferrarese F., Fariselli L., Livi L., Pasqualetti F., Fiorentino A., Alongi F., di Monale M. B., Magrini S., Scorsetti M., Navarria, P, Minniti, G, Clerici, E, Tomatis, S, Pinzi, V, Ciammella, P, Galaverni, M, Amelio, D, Scartoni, D, Scoccianti, S, Krengli, M, Masini, L, Draghini, L, Maranzano, E, Borzillo, V, Muto, P, Ferrarese, F, Fariselli, L, Livi, L, Pasqualetti, F, Fiorentino, A, Alongi, F, di Monale, M, Magrini, S, Scorsetti, M, Navarria P., Minniti G., Clerici E., Tomatis S., Pinzi V., Ciammella P., Galaverni M., Amelio D., Scartoni D., Scoccianti S., Krengli M., Masini L., Draghini L., Maranzano E., Borzillo V., Muto P., Ferrarese F., Fariselli L., Livi L., Pasqualetti F., Fiorentino A., Alongi F., di Monale M. B., Magrini S., and Scorsetti M.

Abstract

Introduction: The prognosis of glioma is dismal, and almost all patients relapsed. At recurrence time, several treatment options are considered, but to date there is no a standard of care. The Neurooncology Study Group of the Italian Association of Radiation Oncology (AIRO) collected clinical data regarding a large series of recurrent glioma patients who underwent re-irradiation (re-RT) in Italy. Methods: Data regarding 300 recurrent glioma patients treated from May 2002 to November 2017, were analyzed. All patients underwent re-RT. Surgical resection, followed by re-RT with concomitant and adjuvant chemotherapy was performed. Clinical outcome was evaluated by neurological examination and brain MRI performed, 1 month after radiation therapy and then every 3 months. Results: Re-irradiation was performed at a median interval time (IT) of 16 months from the first RT. Surgical resection before re-RT was performed in 19% of patients, concomitant temozolomide (TMZ) in 16.3%, and maintenance chemotherapy in 29%. Total doses ranged from 9 Gy to 52.5 Gy, with a median biological effective dose of 43 Gy. The median, 1, 2 year OS were 9.7 months, 41% and 17.7%. Low grade glioma histology (p ≪ 0.01), IT > 12 months (p = 0.001), KPS > 70 (p = 0.004), younger age (p = 0.001), high total doses delivered (p = 0.04), and combined treatment performed (p = 0.0008) were recorded as conditioning survival. Conclusion: our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients. The identification of a BED threshold able to obtain a greater benefit on OS, can help in designing future prospective studies.

Published
2019

23. Correction to: Impact of COVID-19 on patient–doctor interaction in a complex radiation therapy facility

Author

Desideri, Isacco, primary, Francolini, G., additional, Ciccone, L. P., additional, Stocchi, G., additional, Salvestrini, V., additional, Aquilano, M., additional, Greto, D., additional, Bonomo, P., additional, Meattini, I., additional, Scotti, V., additional, Scoccianti, S., additional, Simontacchi, G., additional, and Livi, L., additional

Published
2021
Full Text
View/download PDF

24. Dose-Escalated Accelerated Hypofractionation for Patients With a Newly Diagnosed Glioblastoma: A Pooled International Study

Author

Perlow, H.K., primary, Yang, M., additional, Klamer, B., additional, Marrazzo, L., additional, Detti, B., additional, Scorsetti, M., additional, Clerici, E., additional, Arnett, A.L.H., additional, Beyer, S., additional, Ammirati, M., additional, Grecula, J.C., additional, Chakravarti, A., additional, Raval, R., additional, Navarria, P., additional, Scoccianti, S., additional, and Palmer, J.D., additional

Published
2021
Full Text
View/download PDF

26. Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Author

Reverberi, C, Volpe, S, Balestrini, D, Buglione, M, Navarria, P, Scoccianti, S, Panciani, P, Krengli, M, Pirtoli, L, Bordi, L, Pappagallo, G, Angelillo, R, Magrini, S, Arcangeli, S, Pappagallo, GL, Angelillo, RMD, Magrini, SM, Reverberi, C, Volpe, S, Balestrini, D, Buglione, M, Navarria, P, Scoccianti, S, Panciani, P, Krengli, M, Pirtoli, L, Bordi, L, Pappagallo, G, Angelillo, R, Magrini, S, Arcangeli, S, Pappagallo, GL, Angelillo, RMD, and Magrini, SM

Abstract

Purpose: To perform a systematic review of the current level of evidence on post-operative management following brain metastasectomy (namely: adjuvant stereotactic radiosurgery, whole brain radiotherapy or observation), and to propose a GRADE-based dedicated recommendation to inform Radiation Oncologists’ clinical practice. Methods: A panel of expert Radiation Oncologists from the Italian Association of Radiotherapy and Clinical Oncology had defined the search question per the PICO methodology. Electronic databases were independently screened; the Preferred Reporting Items for Systematic Reviews and Meta-Analyses was adopted. The individual and pooled hazard ratios with 95% confidence intervals (CI), as well as the pooled risk ratio (RR) were calculated using a fixed- or random-effects model. Results: Eight full-texts were retrieved: six retrospective studies and two randomized clinical trials. Outcomes of benefit and damage were analyzed for SRS + observation (PICO A) and SRS + WBRT. SRS allowed for increased rates of local control when compared to both observation and WBRT, while evidence was less conclusive for distant brain control, leptomeningeal disease control and overall survival. In the SRS, the incidence of severe radionecrosis was higher as compared to WBRT, despite neurocognitive deterioration rates were lower. Overall, SRS seems to favorably compare with observation and whole brain RT, despite the level of evidence for the recommendation was low and very low, respectively. Conclusion: Despite low level of evidence, the panel concluded that the risk/benefit ratio probably favors adjuvant SRS as compared to the observation and whole brain RT as adjuvant treatments following brain metastasectomy (5 votes/5 participants, 100% attendance).

Published
2021

31. PD-0175: TTIRS trial:a retrospective analysis of the association between TT or IT and RS for BM from NSCLC

Author

Olmetto, E., primary, Scoccianti, S., additional, Di Franco, R., additional, Anselmo, P., additional, Beltramo, G., additional, Mantovani, C., additional, Osti, M.F., additional, Pinzi, V., additional, Giaj-Levra, N., additional, Bruni, A., additional, Matteucci, P., additional, Pedretti, S., additional, Giudice, E., additional, Tini, P., additional, Krengli, M., additional, Ciammella, P., additional, Pasqualetti, F., additional, Trignani, M., additional, Merlotti, A., additional, Borzillo, V., additional, Franceschini, D., additional, Maranzano, E., additional, Umberto, R., additional, Pierina, N., additional, and Scotti, V., additional

Published
2020
Full Text
View/download PDF

33. PO-0880: SRS in brain metastases from colorectalcancer. A Radiation Oncology Italian Association study

Author

Navarria, P., primary, Clerici, E., additional, Comito, T., additional, Cozzi, S., additional, Pinzi, V., additional, Ciammella, P., additional, Scoccianti, S., additional, Borzillo, V., additional, Anselmo, P., additional, Maranzano, E., additional, Dell'acqua, V., additional, Jereczek-Fossa, B., additional, Levra, N. Giaj, additional, Minniti, G., additional, Podlesko, A.M., additional, Giudice, E., additional, di Monale e Bastia, M. Buglione, additional, Pedretti, S., additional, Bruni, A., additional, Zanetti, I. Bssi, additional, Borgesi, S., additional, Busato, F., additional, and Scorsetti, M., additional

Published
2020
Full Text
View/download PDF

38. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists

Author

Furlan, C, Arcangeli, S, Avanzo, M, Mirri, MA, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, DELI, ANIKO' MARIA, Pavanato, G, Giuliano, FM, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, Donato, V, PINZI, VALENTINA, Furlan, Carlo, Arcangeli, Stefano, Avanzo, Michele, Mirri, Maria A, Munoz, Fernando, Giudici, Stefania, Perrone, Antonio, Amelio, Dante, Tomio, Luigi, Draghini, Loredana, Deli, Aniko M, Pavanato, Giovanni, Giugliano, Francesca M, Pontoriero, Antonio, Ciammella, Patrizia, Navarria, Pierina, Iannalfi, Alberto, Buglione, Michela, Guida, Cesare, Cammelli, Silvia, Iorio, Vincenzo, Cardinali, Massimo, Genovesi, Domenico, Barsacchi, Lucia, Balducci, Mario, Bagnoli, Rita, Berti, Franco, Montesi, Giampaolo, Pasqualetti, Francesco, Bonome, Paolo, Santoni, Riccardo, Doino, Daniela, Schirru, Patrizia, Pinzi, Valentina, Borzillo, Valentina, Ferrarese, Fabio, Ferro, Marica, De Cicco, Luigi, Krengli, Marco, Scoccianti, Silvia, Donato, Vittorio, Furlan, C, Arcangeli, S, Avanzo, M, Mirri, M, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, Deli, A, Pavanato, G, Giuliano, F, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, and Donato, V

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, gliomas (HGG), Radiosurgery, 030218 nuclear medicine & medical imaging, Re-Irradiation, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Glioma, Surveys and Questionnaires, Reirradiation, gliomas (HGG), Medicine, Humans, dose, glioblastoma, glioma, IMRT, radiosurgery, reirradiation, IMRT, Reirradiation, Settore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Salvage Therapy, RECURRENT HIGH GRADE GLIOMA, business.industry, Dose, Glioblastoma, Radiation Oncologists, General Medicine, medicine.disease, Combined Modality Therapy, SURVEY, Current management, Italy, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business
Abstract

Purpose: To assess the contribution of Italian radiation oncologists in the current management of recurrent high-grade gliomas (HGG), focusing on a reirradiation (reRT) approach. Methods: In 2015, the Reirradiation and the Central Nervous System Study Groups on behalf of the Italian Association of Radiation Oncology (AIRO) proposed a survey. All Italian radiation oncologists were individually invited to complete an online questionnaire regarding their clinical management of recurrent HGG, focusing on a reRT approach. Results: A total of 37 of 210 questionnaires were returned (18% of all centers): 16 (43%) from nonacademic hospitals, 14 (38%) from academic hospitals, 5 (13%) from private institutions, and 2 (6%) from hadron therapy centers. The majority of responding centers (59%) treated ≤5 cases per year. Performance status at the time of recurrence, along with a target diameter Conclusions: Although there were wide variations in the clinical practice of reRT across the 37 centers, the core activities were reasonably consistent. These findings provide a basis for encouraging a national collaborative study to develop, implement, and monitor the use of reRT in this challenging clinical setting.

Published
2017

39. PO-0750 VMAT for CNS Tumors and alopecia:results of an observational study and new constraints for the SCALP

Author

Scoccianti, S., primary, Grassi, R., additional, Marco, P., additional, Terziani, F., additional, Simontacchi, G., additional, Talamonti, C., additional, Caramia, G., additional, Russo, M. Lo, additional, Teriaca, M.A., additional, Scoccimarro, E., additional, Saieva, C., additional, Cosi, L., additional, Pallotta, S., additional, and Livi, L., additional

Published
2019
Full Text
View/download PDF

40. OC-0276 Stereotactic radiosurgery plus immunotherapy or targeted therapy for brain metastases from NSCLC

Author

Olmetto, E., primary, Paoli, C. Delli, additional, Ciccone, L.P., additional, Perna, M., additional, Grassi, R., additional, Erika, S., additional, Scoccianti, S., additional, Greto, D., additional, Desideri, I., additional, Simontacchi, G., additional, Marrazzo, L., additional, Arilli, C., additional, Casati, M., additional, Compagnucci, A., additional, Pecchioli, G., additional, Pallotta, S., additional, and Livi, L., additional

Published
2019
Full Text
View/download PDF

44. Policies for reirradiation of recurrent high-grade gliomas: a survey among Italian radiation oncologists

Author

Furlan, C, Arcangeli, S, Avanzo, M, Mirri, M, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, Deli, A, Pavanato, G, Giuliano, F, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, Donato, V, Mirri, MA, DELI, ANIKO' MARIA, Giuliano, FM, PINZI, VALENTINA, Furlan, C, Arcangeli, S, Avanzo, M, Mirri, M, Munoz, F, Giudici, S, Perrone, A, Amelio, D, Tornio, L, Draghini, L, Deli, A, Pavanato, G, Giuliano, F, Pontoriero, A, Ciammella, P, Navarria, P, Lannalfi, A, Buglione, M, Guida, C, Cammelli, S, Lorio, V, Cardinali, M, Genovesi, D, Barsacchi, L, Balducci, M, Bagnoli, R, Berti, F, Montesi, G, Pasqualetti, F, Bonome, P, Santoni, R, Doino, D, Schirru, P, Pinzi, V, Borzillo, V, Ferrarese, F, Ferro, M, De Cicco, L, Krengli, M, Scoccianti, S, Donato, V, Mirri, MA, DELI, ANIKO' MARIA, Giuliano, FM, and PINZI, VALENTINA

Abstract

Purpose To assess the contribution of Italian radiation oncologists in the current management of recurrent high-grade gliomas (HGG), focusing on a reirradiation (reRT) approach. Methods In 2015, the Reirradiation and the Central Nervous System Study Groups on behalf of the Italian Association of Radiation Oncology (AIRO) proposed a survey. All Italian radiation oncologists were individually invited to complete an online questionnaire regarding their clinical management of recurrent HGG, focusing on a reRT approach. Results A total of 37 of 210 questionnaires were returned (18% of all centers): 16 (43%) from nonacademic hospitals, 14 (38%) from academic hospitals, 5 (13%) from private institutions, and 2 (6%) from hadron therapy centers. The majority of responding centers (59%) treated ≤5 cases per year. Performance status at the time of recurrence, along with a target diameter <5 cm and an interval from primary radiation ≥6 months, were the prevalent predictive factors considered for reRT. Sixty percent of reirradiated patients had already received a salvage therapy, either chemotherapy (40%) or reoperation (20%). The most common approach for reRT was fractionated stereotactic radiotherapy to a mean (photon) dose of 41.6 Gy. Conclusions Although there were wide variations in the clinical practice of reRT across the 37 centers, the core activities were reasonably consistent. These findings provide a basis for encouraging a national collaborative study to develop, implement, and monitor the use of reRT in this challenging clinical setting

Published
2018

45. P01.069 Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter retrospective study by the Brain-Study-Group of the Radiation Oncology Italian Association (AIRO)

Author

Navarria, P, primary, Minniti, G, additional, Pinzi, V, additional, Draghini, L, additional, Borzillo, V, additional, Ciammella, P, additional, Scoccianti, S, additional, Amelio, D, additional, Krengli, M, additional, and Buglione di Monale, M, additional

Published
2018
Full Text
View/download PDF

48. OC-0587: Hypofractionated radiotherapy vs temozolomide in glioblastoma RPA V-VI: a randomized phase II trial

Author

Pedretti, S., primary, Masini, L., additional, Turco, E., additional, Triggiani, L., additional, Krengli, M., additional, Meduri, B., additional, Pirtoli, L., additional, Faedi, M., additional, Gatta, R., additional, Scoccianti, S., additional, Ricardi, U., additional, Santoni, R., additional, Magrini, S., additional, and Buglione, M., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results